We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.67%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$735M
AUM Growth
–
Cap. Flow
+$730M
Cap. Flow %
99.32%
Top 10 Hldgs %
55.66%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$78.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$65.1M
3
CELG
Celgene Corp
CELG
+$61.4M
4
BIIB icon
Biogen
BIIB
+$41M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$35.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 84.4%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
51
Madrigal Pharmaceuticals
MDGL
$11.4B
$1.88M 0.26%
+10,764
New +$2.81M
DNDN
52
DELISTED
DENDREON CORPORATION
DNDN
$1.55M 0.21%
+376,728
New +$1.6M
CERE
53
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$1.3M 0.18%
+52,060
New +$1.08M
ACHV icon
54
Achieve Life Sciences
ACHV
$647M
$1.11M 0.15%
+51
New +$1.14M
LITS
55
Lite Strategy Inc
LITS
$33.6M
$1.06M 0.14%
+7,441
New +$1.24M
SUPN icon
56
Supernus Pharmaceuticals
SUPN
$2.65B
$905K 0.12%
+140,800
New +$829K
ECYT
57
DELISTED
Endocyte, Inc. Common Stock
ECYT
$790K 0.11%
+60,200
New +$812K
ICAD
58
DELISTED
iCAD Inc
ICAD
$531K 0.07%
+88,527
New +$488K
CRTX
59
DELISTED
CORNERSTONE THERAPEUTICS INC
CRTX
$529K 0.07%
+66,112
New +$557K
GCVRZ
60
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$200K 0.03%
+103,665
New +$182K
1 2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Tekla Capital Management, which disclosed 60 positions worth $735M. Its ten largest holdings account for 56% of the portfolio.

Its largest position is Gilead Sciences: 1,504,712 shares worth $77.1M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, followed by Financials.

  • Tekla Capital Management's largest Q2 2013 buy was Gilead Sciences: 1,504,712 shares worth $77.1M.
  • Tekla Capital Management's ten largest holdings make up 56% of its $735M portfolio in Q2 2013.
  • Tekla Capital Management disclosed 60 positions in Q2 2013, its first 13F filing on record.

Based on Tekla Capital Management's 13F filing for Q2 2013, filed 31 Jul 2013.